Sharemaestro Newsreel

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 8.7% - Should You Buy?

Haleon (NYSE:HLN) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Royal Bank of Canada Buys 434,805 Shares of Dr. Reddy's Laboratories Ltd $RDY

Cronos Group Inc (CRON) Institutional Confidence

This article provides details on the institutional confidence score for Cronos Group Inc. (CRON), which remains at 3.00, with no change. It lists the top institutional shareholders and their recent activity, showing significant increases in holdings by D. E. Shaw & Co., L.P. and …

Indivior PLC (INDV) Financial Health: Profitability & Balance Sheet Analysis

Indivior PLC (INDV) has a current financial score of 7.94, ranking 87th out of 155 in the Pharmaceuticals industry, indicating a weak financial status despite high operating efficiency. The company reported a 19.17% year-over-year increase in quarterly revenue to $317.00 million and a 93.48% …

Possible Generic Drug Tariffs and 2 Microcaps

This article discusses the potential impact of proposed tariffs on imported generic drugs, which could reach 100-200%, and examines two microcap companies, Elite Pharmaceuticals (ELTP) and Cumberland Pharmaceuticals (CPIX), that might be affected. ELTP, a domestic manufacturer, could benefit from competitors facing tariffs, while …

Alpha Teknova Inc (TKNO) Institutional Confidence

This article analyzes Alpha Teknova Inc.'s (TKNO) institutional confidence, noting its current score of 7.00, placing it 78th in its industry. Institutional shareholding stands at 85.48%, an increase of 2.70% quarter-over-quarter. The largest institutional shareholder is Chuck Royce, holding 1.99% of outstanding shares.

AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125

This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly …

ETFs Investing in Lantheus Holdings Inc Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Lantheus Holdings Inc. The ETFs are sorted by market value and provide details such as issuer, management style, focus, expense ratio, AUM, price, and 3-year total return. This information helps investors identify …

Tilray Brands (NASDAQ:TLRY) Stock Price Up 5.3% - Should You Buy?

Tilray Brands (NASDAQ:TLRY) saw its stock price increase by 5.3% on Thursday, reaching $4.20 on high volume, although it remains near multiyear lows with profitability concerns. Despite record fiscal 2026 revenue of $915 million and growth in international medical cannabis, the company reported a …

Teva (TEVA) Stock Faces Earnings Shock Despite Strong Brand Growth

Teva Pharmaceutical Industries (TEVA) saw its stock inch up despite reporting a significant net loss of US$576 million in Q2 2026, primarily due to acquisition-related R&D charges. While overall revenue remained steady, the company's branded neurology assets, including AUSTEDO, AJOVY, and UZEDY, showed strong …

Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lifecore Biomedical Inc (LFCR), focusing on its price momentum, support and resistance levels, and various technical indicators, including moving averages. The current price momentum score is 4.32, with the stock trading between a resistance level of 5.16 …

Takeda Pharmaceutical Maintained at "Neutral" by Major U.S. Securities Firm, Target Price Raised to ¥5,800

A major U.S. securities firm maintained its "Neutral" rating on Takeda Pharmaceutical but raised its target price to ¥5,800 following the company's April-June 2026 quarter results. While revenue increased due to a weaker yen, net profit declined due to higher SG&A and R&D expenses, …

Perrigo declares $0.29 quarterly dividend, payable Sept. 15

Perrigo Company plc (NYSE:PRGO) has announced a quarterly dividend of $0.29 per share, to be paid on September 15, 2026, to shareholders of record as of August 28, 2026. This translates to an annualized dividend of $1.16 per share. The company, a consumer self-care …

SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for SCYNEXIS Inc (SCYX), noting its current valuation score of 9.32, ranking 21st in the Pharmaceuticals industry. It highlights the company's current P/E ratio of -10.06, which is significantly below its recent high. The article also indicates that …

Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook

Bausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company's profit recovery. In an updated report, the pharmaceutical giant said that it swung to …

Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), focusing on its stock price momentum, support and resistance levels, and various technical indicators. The current price momentum score is 4.70, ranking 44th in the Pharmaceuticals industry, with the stock trading between a …

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

(RTTNews) - Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept …

Journey Medical Corp (DERM) Cash Flow

This article provides a detailed cash flow statement for Journey Medical Corp (DERM), presenting quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income from continuing operations, changes in working capital, capital expenditures, and net …

Millennium group (NASDAQ: PAHC) discloses 1.06M-share Phibro Animal Health position

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported beneficial ownership of 1,064,608 shares of Phibro Animal Health Corporation (PAHC) Class A common stock, which represents 5.1% of the class. They indicate shared voting and dispositive power over these shares, …

Zoetis, Inc. Class A Revenue Breakdown – MUN:ZOE

This article provides a revenue breakdown for Zoetis, Inc. Class A (MUN:ZOE), highlighting its top-performing segment and geographical contributions. In the last fiscal year, the company generated €8.06 billion in revenue, with the Parasiticides segment contributing €1.99 billion and the United States accounting for …

Perrigo Company plc (NYSE:PRGO) to Issue Quarterly Dividend of $0.29

Perrigo Company plc (NYSE:PRGO) announced a quarterly dividend of $0.29 per share, payable September 15th to shareholders of record on August 28th. This represents an annualized dividend of $1.16 and an 11.2% yield. The company has consistently increased its dividend for 23 consecutive years, …

Form 4 Neurocrine Biosciences Inc For: 30 July By Investing.com

This article reports on a Form 4 filing for Neurocrine Biosciences Inc, specifically for activity on July 30th. It prominently displays the company's stock symbol NBIX and its recent percentage change in value. The content primarily consists of section headers and navigation links, with …

Investors Purchase High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Investors recently purchased a high volume of put options on Teva Pharmaceutical Industries (NYSE:TEVA), signaling increased hedging or defensive positioning, though not a clear market direction. This comes amidst mixed quarterly results where revenue beat expectations, leading to raised 2026 revenue guidance, but EPS …

Neurocrine Biosciences Releases Q2 2026 Financial Results

Neurocrine Biosciences reported strong Q2 2026 financial results, with non-GAAP earnings per share of $2.85, significantly beating analyst expectations, and revenue reaching $959.0M, an 8.0% increase over forecasts. The company's flagship product, INGREZZA, contributed $716.0M to revenue, and full-year revenue guidance was set between …

Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Collegium Pharmaceutical Inc (COLL), noting its current valuation score of 8.50, which ranks 55 out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 15.00, comparing it to recent highs and lows. The …

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) exceeded Q2 earnings and revenue estimates, reporting $2.85 per share against an expected $2.26, and revenues of $959 million, beating the $901.6 million consensus. The company has a strong track record of surpassing estimates and its shares have gained 27.5% year-to-date, …

ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells 2,850 Shares of Stock

ANI Pharmaceuticals' (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company's stock for $231,876, reducing his stake by 1.61%. Despite this insider sale, the company reported strong Q1 earnings, beating analyst expectations with 20.5% year-over-year revenue growth. Analysts maintain a "Moderate Buy" rating …

Bausch Health (NYSE: BHC) posts $1.17B H1 loss after $1.43B goodwill hit

Bausch Health (NYSE: BHC) reported a net loss of $1.17 billion for the first half of 2026, primarily due to a $1.43 billion goodwill impairment in its Salix reporting unit. This impairment followed failed Phase 3 clinical trials for a rifaximin formulation. Despite the …

HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and New Approvals Drive Profitability

HUTCHMED (China) Ltd reported strong product sales growth and new drug approvals in H1 2026, leading to continued profitability with a net income of $60 million and a $1.4 billion cash reserve. The company is advancing its novel ATTC pipeline with two first-in-class assets …

XERS|Xeris Biopharma Holdings Inc|Price:8.415|Chg%:+0.035

This article provides a detailed financial overview of Xeris Biopharma Holdings Inc (XERS), including its stock price, market cap, P/E ratio, and upcoming earnings date. It presents comprehensive financial statements like the income statement, balance sheet, and cash flow statement, broken down quarterly and …

Neurocrine Biosciences Q2 revenue rises 39% to $959 million

Dr Reddy's Laboratories Number of Employees 2026 | Employee Count & Headcount Data

Dr Reddy's Laboratories had approximately 28,123 employees worldwide as of March 2026, representing a 3.0% growth from 2023. The company is actively hiring with 449 job postings in 2026 and its workforce is primarily concentrated in South Asia. The average salary is $16,666 globally, …

Hutchmed returns to revenue growth in first half of 2026

Hutchmed (HCM.US; 0013.HK) reported a slight revenue increase in the first half of 2026, driven by double-digit growth in its oncology and immunology drugs which offset declines in other ventures. While revenue rose by 0.2% to $278.3 million, net income significantly dropped to $15.9 …

Tilray Brands, Inc. (TLRY) director gets 43,104 shares, 62,657 RSUs

Tilray Brands, Inc. director Steven Michael Cohen reported changes in his equity holdings, including the vesting of 43,104 Restricted Stock Units (RSUs) on July 29, 2026, which converted into common shares. Following this, his beneficial common stock ownership increased to 55,542 shares. Additionally, Cohen …

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics, Inc. LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of …